Details for Patent: 8,314,083

Which drugs does patent 8,314,083 protect, and when does it expire?

Patent 8,314,083 protects QUZYTTIR and is included in one NDA.

This patent has five patent family members in five countries.

Summary for Patent: 8,314,083

Patent landscape, scope, and claims:

Title:	Non-sedating antihistamine injection formulations and methods of use thereof
Abstract:	Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions therewith.
Inventor(s):	Du; Jie (Lansdale, PA)
Assignee:	JDP Therapeutics, Inc. (Lansdale, PA)
Application Number:	12/829,857
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,314,083

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jdp	QUZYTTIR	cetirizine hydrochloride	SOLUTION;INTRAVENOUS	211415-001	Oct 4, 2019		RX	Yes	Yes						METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA

International Family Members for US Patent 8,314,083

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010266103
Canada	2803987
European Patent Office	2477634